We further tested the effect of SGLT2 inhibition on prostate cancer risk adjusted for T2DM using a multivariable MR model, and we found that the effect of SGLT2 inhibition on prostate cancer was independent of its effect on T2DM (Table S10B). Here, SLC5A2 is linked to prostate carcinoma.